Crossovers back Affinivax in $226M round as more pipeline vaccines move toward clinic

A $226 million crossover round could set up Affinivax for a public listing as the biotech looks to take more vaccines into the clinic beyond its partnered pneumococcal program.

Rock Springs Capital and Foresite Capital led the new series C round for Cambridge, Mass.-based Affinivax Inc., which has raised $346 million since April 2020...